|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZBTB7C |
Gene summary for ZBTB7C |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZBTB7C | Gene ID | 201501 |
| Gene name | zinc finger and BTB domain containing 7C | |
| Gene Alias | APM-1 | |
| Cytomap | 18q21.1 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A1YPR0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 201501 | ZBTB7C | CA_HPV_3 | Human | Cervix | CC | 5.34e-06 | 1.53e-01 | 0.0414 |
| 201501 | ZBTB7C | CCI_1 | Human | Cervix | CC | 9.64e-13 | 1.26e+00 | 0.528 |
| 201501 | ZBTB7C | CCI_2 | Human | Cervix | CC | 7.91e-05 | 9.14e-01 | 0.5249 |
| 201501 | ZBTB7C | CCI_3 | Human | Cervix | CC | 4.32e-25 | 2.04e+00 | 0.516 |
| 201501 | ZBTB7C | sample3 | Human | Cervix | CC | 6.09e-03 | 1.29e-01 | 0.1387 |
| 201501 | ZBTB7C | T3 | Human | Cervix | CC | 3.62e-02 | 1.50e-01 | 0.1389 |
| 201501 | ZBTB7C | HTA11_3410_2000001011 | Human | Colorectum | AD | 3.49e-04 | -3.27e-01 | 0.0155 |
| 201501 | ZBTB7C | HTA11_2487_2000001011 | Human | Colorectum | SER | 9.68e-05 | 5.57e-01 | -0.1808 |
| 201501 | ZBTB7C | HTA11_78_2000001011 | Human | Colorectum | AD | 1.91e-02 | 5.12e-01 | -0.1088 |
| 201501 | ZBTB7C | HTA11_347_2000001011 | Human | Colorectum | AD | 4.13e-26 | 9.76e-01 | -0.1954 |
| 201501 | ZBTB7C | HTA11_411_2000001011 | Human | Colorectum | SER | 5.35e-03 | 8.21e-01 | -0.2602 |
| 201501 | ZBTB7C | HTA11_83_2000001011 | Human | Colorectum | SER | 3.39e-13 | 9.60e-01 | -0.1526 |
| 201501 | ZBTB7C | HTA11_696_2000001011 | Human | Colorectum | AD | 6.70e-15 | 9.12e-01 | -0.1464 |
| 201501 | ZBTB7C | HTA11_866_2000001011 | Human | Colorectum | AD | 3.10e-03 | 5.29e-01 | -0.1001 |
| 201501 | ZBTB7C | HTA11_5212_2000001011 | Human | Colorectum | AD | 6.88e-03 | 6.23e-01 | -0.2061 |
| 201501 | ZBTB7C | HTA11_546_2000001011 | Human | Colorectum | AD | 2.37e-04 | 7.14e-01 | -0.0842 |
| 201501 | ZBTB7C | HTA11_866_3004761011 | Human | Colorectum | AD | 1.23e-04 | -3.49e-01 | 0.096 |
| 201501 | ZBTB7C | HTA11_7663_2000001011 | Human | Colorectum | SER | 1.40e-02 | 5.92e-01 | 0.0131 |
| 201501 | ZBTB7C | HTA11_99999970781_79442 | Human | Colorectum | MSS | 6.84e-16 | -4.66e-01 | 0.294 |
| 201501 | ZBTB7C | HTA11_99999971662_82457 | Human | Colorectum | MSS | 6.29e-30 | -6.78e-01 | 0.3859 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:005109810 | Cervix | CC | regulation of binding | 80/2311 | 363/18723 | 1.32e-07 | 6.42e-06 | 80 |
| GO:00454445 | Cervix | CC | fat cell differentiation | 53/2311 | 229/18723 | 3.72e-06 | 9.75e-05 | 53 |
| GO:005110110 | Cervix | CC | regulation of DNA binding | 31/2311 | 118/18723 | 2.91e-05 | 4.81e-04 | 31 |
| GO:0045598 | Cervix | CC | regulation of fat cell differentiation | 31/2311 | 139/18723 | 7.06e-04 | 6.41e-03 | 31 |
| GO:00456004 | Cervix | CC | positive regulation of fat cell differentiation | 18/2311 | 66/18723 | 8.09e-04 | 7.07e-03 | 18 |
| GO:0051098 | Colorectum | AD | regulation of binding | 126/3918 | 363/18723 | 6.01e-10 | 4.88e-08 | 126 |
| GO:0051101 | Colorectum | AD | regulation of DNA binding | 42/3918 | 118/18723 | 1.62e-04 | 2.23e-03 | 42 |
| GO:00510981 | Colorectum | SER | regulation of binding | 97/2897 | 363/18723 | 1.98e-08 | 1.43e-06 | 97 |
| GO:00511011 | Colorectum | SER | regulation of DNA binding | 33/2897 | 118/18723 | 3.70e-04 | 5.71e-03 | 33 |
| GO:0045444 | Colorectum | SER | fat cell differentiation | 51/2897 | 229/18723 | 3.96e-03 | 3.26e-02 | 51 |
| GO:0045600 | Colorectum | SER | positive regulation of fat cell differentiation | 19/2897 | 66/18723 | 4.29e-03 | 3.45e-02 | 19 |
| GO:00510982 | Colorectum | MSS | regulation of binding | 113/3467 | 363/18723 | 3.55e-09 | 2.41e-07 | 113 |
| GO:00511012 | Colorectum | MSS | regulation of DNA binding | 37/3467 | 118/18723 | 5.29e-04 | 5.99e-03 | 37 |
| GO:00510984 | Colorectum | FAP | regulation of binding | 81/2622 | 363/18723 | 1.04e-05 | 2.97e-04 | 81 |
| GO:00510985 | Colorectum | CRC | regulation of binding | 72/2078 | 363/18723 | 6.43e-07 | 4.50e-05 | 72 |
| GO:005109825 | Esophagus | HGIN | regulation of binding | 78/2587 | 363/18723 | 3.73e-05 | 9.30e-04 | 78 |
| GO:005110125 | Esophagus | HGIN | regulation of DNA binding | 28/2587 | 118/18723 | 2.54e-03 | 2.51e-02 | 28 |
| GO:0051098111 | Esophagus | ESCC | regulation of binding | 251/8552 | 363/18723 | 6.73e-20 | 8.46e-18 | 251 |
| GO:0051101111 | Esophagus | ESCC | regulation of DNA binding | 84/8552 | 118/18723 | 1.64e-08 | 3.21e-07 | 84 |
| GO:00454449 | Esophagus | ESCC | fat cell differentiation | 135/8552 | 229/18723 | 3.38e-05 | 2.78e-04 | 135 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ZBTB7C | PTC | Thyroid | ATC | CTSH,CXCL17,SERPINA1, etc. | 4.20e-01 |  |
| ZBTB7C | iATC | Thyroid | ATC | CTSH,CXCL17,SERPINA1, etc. | 1.81e-01 | |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZBTB7C | SNV | Missense_Mutation | novel | c.548N>C | p.Ile183Thr | p.I183T | A1YPR0 | protein_coding | tolerated(0.74) | benign(0.007) | TCGA-BH-A1FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| ZBTB7C | SNV | Missense_Mutation | c.1091A>C | p.Gln364Pro | p.Q364P | A1YPR0 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-E9-A1N5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| ZBTB7C | SNV | Missense_Mutation | c.83N>A | p.Arg28Gln | p.R28Q | A1YPR0 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-GM-A3XN-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR | |
| ZBTB7C | insertion | Frame_Shift_Ins | novel | c.61_62insCATACCGGGGAGAAGCCATACA | p.Leu21ProfsTer13 | p.L21Pfs*13 | A1YPR0 | protein_coding | TCGA-A2-A0CM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | PD | ||
| ZBTB7C | insertion | Nonsense_Mutation | novel | c.578_579insTTTATGAGTTACATGGAGGCTAGTTAAGAGTGTGGTATAGAAC | p.His194LeufsTer2 | p.H194Lfs*2 | A1YPR0 | protein_coding | TCGA-A8-A097-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| ZBTB7C | insertion | In_Frame_Ins | novel | c.301_302insAAGGAAGTGAGGCGCCTCAAGCACCTTGGTTGCTTGGCTTCCTCTTCT | p.Ala101delinsGluGlySerGluAlaProGlnAlaProTrpLeuLeuGlyPheLeuPheSer | p.A101delinsEGSEAPQAPWLLGFLFS | A1YPR0 | protein_coding | TCGA-B6-A0I6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | ||
| ZBTB7C | SNV | Missense_Mutation | novel | c.1709N>T | p.Ala570Val | p.A570V | A1YPR0 | protein_coding | tolerated_low_confidence(0.08) | benign(0.236) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ZBTB7C | SNV | Missense_Mutation | c.463N>A | p.Glu155Lys | p.E155K | A1YPR0 | protein_coding | tolerated(0.14) | benign(0.075) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZBTB7C | SNV | Missense_Mutation | novel | c.1165G>A | p.Glu389Lys | p.E389K | A1YPR0 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-ZJ-AAXB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| ZBTB7C | SNV | Missense_Mutation | rs774830243 | c.1199N>A | p.Arg400His | p.R400H | A1YPR0 | protein_coding | deleterious(0.01) | benign(0.052) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |